GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (LTS:0LIF) » Definitions » Inventories, Work In Process

Ultragenyx Pharmaceutical (LTS:0LIF) Inventories, Work In Process : $22.8 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ultragenyx Pharmaceutical Inventories, Work In Process?

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Ultragenyx Pharmaceutical's work in process for the quarter that ended in Mar. 2024 was $22.8 Mil.


Ultragenyx Pharmaceutical Inventories, Work In Process Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Inventories, Work In Process Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.19 7.18 10.50 17.49 18.86

Ultragenyx Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.09 18.54 19.17 18.86 22.82

Ultragenyx Pharmaceutical Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.


Ultragenyx Pharmaceutical (LTS:0LIF) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (LTS:0LIF) Headlines

No Headlines